Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a Chinese endovascular device manufacturer, has reported its financial results for the first half of 2024, demonstrating robust growth. The company’s revenue reached RMB 787 million, marking a 26.63% increase year-on-year (YOY). The operating profit soared to RMB 472 million, a 44.46% YOY increase, while the net profit stood at RMB 403 million, up 44.36% YOY. A significant portion of the company’s operating income, 11.98%, was allocated to R&D, amounting to an investment of RMB 94.2913 million.
The company’s innovative products, including the Castor branched aortic stent graft and delivery system, Minos abdominal aortic stent graft and delivery system, and Reewarm PTX drug balloon dilation catheter, have exhibited outstanding clinical performance. Additionally, the Talos straight tube thoracic aortic stent graft system and Fontus branched intraoperative stent system have experienced accelerated adoption in hospitals and post-implantation settings.
By June 2024, MicroPort Endovascular MedTech had filed a total of 708 patent applications, with 110 being authorized overseas patents. The company’s commitment to innovation has led to the approval of 8 of its products, either already commercialized or in development, to enter the national innovation medical device approval “green channel.”
The company has strategically focused on marketing efforts in second, third, and fourth-tier cities and counties with large populations, aiming to expand its market reach and cater to the healthcare needs of these regions.- Flcube.com
